Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: jayhawk969 who wrote (23350)	7/19/1998 11:51:00 PM
From: Henry Niman	Respond to of 32384

JD, I don't think that there is much of an intersection between LGND and genomics, which is one of the reasons that I think genomics companies will have a bumpy road. Genomics companies could create some major markets in the diagnosis and prognosis area, but I don't expect much in the therapeutics area. In therapeutics, there are already many known targets. LGND alone is look at about 100 and each target lends itself to thousands of analogs. Usually genomics is just a very expensive way of discovering an interesting target. After discovery, the types of modifications that LGND and others do are required before pre-clinical testing gets rolling, and then there are the same clinical trails that everyone must run. I think that genomics will go a long way towards identifying susceptible individuals and it will probably identify subtypes that will and won't respond to various treatments. However, LGND focuses on therapeutics, and I don't see major advances from genomics in that arena.